NICE U-turn on Alzheimer's guidance
This article was originally published in Scrip
NICE has today backtracked on earlier controversial guidance rejecting Pfizer/Eisai's Aricept (donepezil), Shire's Reminyl (galantamine) and Novartis's Exelon (rivastigmine) for treating patients with mild Alzheimer's disease as well as Lunbeck's Ebixa (memantine) for severe disease. Some new evidence and a new economic model looking at the cost-effectiveness of acetylcholinesterase (AChE) inhibitors are key to the change of heart.
You may also be interested in...
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.